Helen E. Rich

Also affiliated with Cerevel Therapeutics (United States)

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Insights Into Type I and III Interferons in Asthma and Exacerbations”.

Insights Into Type I and III Interferons in Asthma and Exacerbations

Frontiers in Immunology(2020)10.3389/fimmu.2020.574027

N/A

0DataRank · unranked

54 citations

Danielle Antos, Natalie R. Melton, John F. Alcorn, Michelle L. Manni, Helen E. Rich

Murine Type III interferons are functionally redundant and correlate with bacterial burden during influenza/bacterial super-infection

PLoS ONE(2021)10.1371/journal.pone.0255309

N/A

0DataRank · unranked

8 citations

Danielle Antos, Collin C. McCourt, Wen Zheng, Louis DeVito, Kevin J. McHugh +4 more

A multivalent nanobody–drug conjugate to prevent and treat influenza virus infections

Proceedings of the National Academy of Sciences(2025)10.1073/pnas.2409565122

N/A

0DataRank · unranked

4 citations

Laura Pietrok, Helen E. Rich, Rhogerry Deshycka, Laney Flanagan, Aaron Accardo +3 more